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Background: Based on the dynamics of antigen recognition from T cell receptor complex and T cell activation,
different function of T cells may present different morphology feature, at least at molecular level. Regulatory
T (Treg) cells play a critic role in regulation the onset of graft versus host disease (GVHD) after allogeneic
hematopoietic stem cell transplantation (allo-HSCT). Little is known about their morphology feature which may
relate to the regulating function in GVHD.
Results: In this study, we detected the biophysical architectural changes of specific Treg cells subsets after
allo-HSCT using biological atomic force microscopy to characterize their biological characteristics and improve
our understanding of cell structure-function relationships in GVHD. There were dramatic overall shape and surface
membrane deformations of the Treg cells associated with patients at GVHD onset or without GVHD. The Treg cells
at GVHD onset or without GVHD could be distinguished by the morphologic parameters of morphology, membrane
nanostructure, and membrane pore. These AFM parameters of Treg cells morphology differed obviously between
GVHD and without GVHD. The multiple irregular microspikes could be observed on the surface of Treg cells without
GVHD.
Conclusions: The remarkable biological morphology changes in the cell membrane structure of Treg cells after
allo-HSCT might be related to the function of Treg cells which could inhibit the occurrence and development of GVHD.
Keywords: Atomic force microscopy, Regulatory T cells, Graft versus host disease, Allogeneic hematopoietic stem cell
transplantationBackground
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is an important therapeutic option for a number of
malignant and refractory hematological diseases. Graft
versus host disease (GVHD) is the main complications
following allo-HSCT. GVHD is primarily a donor T cell-
mediated syndrome whereby T cells in the graft elicit an
immune response, resulting in host tissue damage [1,2].
Knowledge of the immunobiology underlying GVHD has
advanced by virtue of immunology research in animal
models, as well as clinical observations. GVHD occurs as aCorrespondence: siulier@163.com; yangqiuli@hotmail.com
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unless otherwise stated.result of T cell activation followed by allo-reactive T cell
expansion and differentiation [3]. Since GVHD is charac-
terized by the loss of tolerance and the development of
autoimmune manifestations, it is reasonable to indicate
that a deficiency in regulatory T (Treg) cells reconstitution
plays a critical role in GVHD pathophysiology and might
participate in mediating GVHD and graft-versus-leukemia
(GVL) effect after allo-HSCT [4,5]. The Treg cells, which
identified suppressive population of CD4+ T cells that
expressed high levels of the IL-2 receptor α-chain (CD25)
formerly known as suppressor T cells, are a subpopulation
of T cells which modulate the immune system, maintain
tolerance to self-antigens, and abrogate autoimmune
disease [1,6,7]. Mouse models have suggested that modula-
tion of Treg cells can treat autoimmune disease and cancer,
and facilitate organ transplantation [1,3,8], while the mole-
cular mechanism of Treg cells is still unclear. Rapidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(AFM) have allowed researchers to investigate the
behavior of single living cells [9,10]. Using AFM to
understand the correlation between intracellular chemical
processes and cellular physical properties will significantly
improve our understanding of physiological events. All
the changes in cell ultrastructure help us to better
understand the structure–function relationships. The
AFM applications have the possibility to detect the early
subtle changes before significant pathology occur and to
give the decision which time to terminate the treatment
[11,12]. Thus, to further understand the biological charac-
teristics of specific Treg cells subsets related to GVHD, in
this study, we detected the biophysical architectural




Thirty leukemia patients (15 males and 15 females, me-
dian age, 30.6 years; range, 20 ~ 46 years) were monitored
prospectively after allo-HSCT. The diagnosis was based
on the criteria reported in the guidelines of American
Society of Hematology. According to WHO classification
[13], those 30 patients with leukemia included 16 cases
with acute myeloid leukemia (AML), 10 cases with
chronic myeloid leukemia (CML), and 4 cases with acute
lymphoid leukemia (ALL). Acute and chronic GVHD were
diagnosed and graded as previously described [14].
Ethics and consent statement
All of the procedures were conducted according to the
guidelines of the Medical Ethics Committee of the health
bureau of the Guangdong Province of China (Registra-
tion number: NUMD-201303), in compliance with the
Helsinki Declaration. Likewise, adult participants in the
study (all human subjects) provided informed consent
for blood donation.
Treg cells isolation
The Treg cells were obtained from freshly acquired peri-
pheral blood samples in patients at GVHD onset and pa-
tients who did not develop GVHD at the same time point.
Peripheral blood mononuclear cells (PBMCs) were isolated
from peripheral blood samples by Ficoll-Hypaque gradient
centrifugation. The CD4 +CD25+ Treg cells were sorted
from PBMCs using human CD4 + CD25+ Treg cells iso-
lation Kit and MACS® magnetic cell sorting technique
(Miltenyi Biotec, Bergisch Gladbach, Germany) [15].
Atomic force microscope measurement
The cell suspension (CD4 + CD25+ cells from cases with
GVHD, CD4 + CD25- cells from cases with GVHD,
CD4 + CD25+ cells from cases without GVHD, CD4 +CD25- cells from cases without GVHD respectively) was
dropped on glass cover slips and fixed in 4% paraformal-
dehyde and air dried prior to atomic force microscope
(AFM) scanning and phasecontrast micrograph. Topo-
graphic images of cells were obtained using an AFM
(Autoprobe CP Research, Veeco) in contact mode. In
all AFM experiments, gold-coated silicon nitride tips
(UL20B; Park Scientific Instruments) with a spring con-
stant of 2.5 N/m and a tip diameter of 20 nm were used.
An optical microscope was used to help select the de-
sired cells and direct the position of the AFM tip.
Single-cell imaging was performed for five cells of each
condition, and each cell was scanned three times. To
gain information on the topography of the cell, all
images were analyzed using the instrument-equipped
IP2.1 software (Veeco Metrology Group, Santa Barbara,
CA). The area analyzed with AFM was a 10 μm× 10 μm
square. The length (L) and width (W) defined the
maximum and minimum values of the cell diameter,
respectively. The r defines the ratio of L/W. The peak
(H) value means the maximum height values of the cell
membrane surface. The surface roughness value Ra was
analyzed for each sample. This value defined the mean
value of the surface roughness in the area being ana-
lyzed. All these parameters were directly determined
using the IP2.1 software [12,16].
Roughness: Ra ¼ 1=Nð Þ
XN
n¼1 Zn−
Zj j. Z : given by the
average height within the included areas defined by a
region group Z ¼ 1=Nð Þ
XN
n¼1Zn . The Z is the height
profile line based on the surface.Statistical analysis
Differences between numerical variables were calculated
by means of the one-way ANOVA (the Welch test). The
P values were two tailed, and P < 0.05 was considered
statistically significant. The SPSS software package 13.0
(SPSS, Chicago, IL) was used for all data analysis.Results and discussion
All patients achieved hematopoietic reconstitution. The
median time for neutrophils (absolute neutrophils
counts > 0.5 × 109/L) and platelets (platelets counts >
20 × 109/L) engraftment was 12 and 15 days, respec-
tively. Of the 30 patients, the incidence of total GVHD
was 73.3% (n = 22), while 8 patients were without acute
or chronic GVHD. The incidence of I° ~ IV° and III° ~ IV°
acute GVHD including acute GVHD after transplantation
was 63.3% (n = 19) and 13.3% (n = 4), respectively. Of the
30 patients who survived more than 100 days after trans-
plantation, the incidence of limited and extensive chronic
GVHD was 33.3% (n = 10) and 6.7% (n = 2), respectively.
Therefore, in this study, we compared the biophysical
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cases) and patients with GVHD (including acute and/or
chronic GVHD, 22 cases) after allo-HSCT.
The AFM was used to study the biophysical properties
(the parameters including morphology, membrane nano-
structure, membrane pore, adhesion, distribution and so
on) of Treg cells at GVHD onset or without GVHD. The
overall shape of Treg cell was shown an oval shape. The
r (L/W) value was nearly equal to 1. The AFM morpho-
logical images of Treg cells were shown in Figure 1. The
total CD4 +CD25+ cells (including from patients with
GVHD and without GVHD) formed a higher and bigger
round shape and abundant protrusions compared with the
total CD4 +CD25- cells (including from patients with
GVHD and without GVHD) (Figure 1A,B). The cell surface
architecture in the Treg cells showed more irregular micro-
spikes especially in the cell surface center. The irregular
microspikes or nano clusters might be the ultrastructure
membrane proteins which were reorganized the specific
antigens and corresponding to the large change in the
structure of the cells surface. Moreover, the CD4 +CD25+
cells with GVHD showed smaller and more irregular shape
compared with the CD4 +CD25+ cells without GVHD
(Figure 1C,D). The cell surface architecture had been ser-
iously deformed, and the cell surface center atrophied and
no longer had a regular normal Treg cells’ shape.
The biophysical property data of Treg cells from all
samples measured by AFM were showed in the Table 1.Figure 1 AFM images of Treg cells. A: AFM three-dimensional images of C
C: AFM three-dimensional images of CD4 + CD25+ cells at GVHD onset; D: AFThe average surface fluctuation Ra of the Treg cells without
GVHD were significant increased in comparison with that
of the Treg cells with GVHD (P < 0.001). However, by
measuring the adhesion force of the cells, there was no
significant difference in the stiffness between the total
CD4 + CD25- cells and the total CD4 + CD25+ cells
groups (5.23 ± 0.43 vs. 5.51 ± 0.67, P = 0.2807), or between
the CD4 +CD25+ cells with GVHD and the CD4 +CD25+
cells without GVHD groups (5.37 ± 0.49 vs. 5.72 ± 0.31,
P = 0.0710).
It is well known that the main complication of allo-
HSCT is GVHD, an immunological disorder that affects
many organ systems, including the gastrointestinal tract,
liver, skin, and lungs [4]. Development of novel strategies
that use donor leukocyte infusions, non-myeloablative
conditioning, and umbilical-cord blood transplantation
has helped expand the application of HSCT over the
past few years [17]. Moreover, clinical approaches that
restore effective immune regulation are therefore an
attractive treatment strategy for GVHD. Treg cells which
are potent suppressors of immune responses have been
a focal point of research studies designed to mitigate the
severity of GVHD in both pre-clinical murine models
and in early stage clinical trials [1,3,8]. In fact, studies in
mice have demonstrated that there is a progressive loss
of Treg cells during GVHD, and this leads to the emer-
gence of autoreactive proinflammatory donor T cells.
The initial phase of GVHD might be associated with aD4 + CD25+ cells; B: AFM three-dimensional images of CD4 + CD25- cells;
M three-dimensional images of CD4 + CD25+ cells without GVHD.








Total CD4 + CD25+ cells 12.04 ± 0.24 3.95 ± 0.27 250.83 ± 82.39
Total CD4 + CD25- cells 10.23 ± 1.54 3.27 ± 0.32 110.45 ± 22.11
P values* < 0.001 < 0.001 < 0.001
CD4 + CD25+ with GVHD 11.96 ± 0.17 3.85 ± 0.14 191.33 ± 75.22
CD4 + CD25+ without GVHD 12.12 ± 0.13 4.12 ± 0.21 311.67 ± 18.45
P values* 0.032 < 0.001 < 0.001




Zj j; Z : given by the average height
within the included areas defined by a region group Z ¼ 1=Nð Þ
XN
n¼1Zn; The Z
is the height profile line based on the surface.
*Compared by the Welch test.
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blood of patients after allo-HSCT [18]. The CD4+ CD25+
Treg frequencies measured within 24 hrs of GVHD
diagnosis were significantly less than patient without
GVHD, and correlated inversely with GVHD severity
[19]. There will be a promising application in use of
adoptive immunotherapy within CD4+ CD25+ Treg
cells to treat GVHD patients, however, the biological
characteristics of specific Treg cells are still unknown,
and that may limit its further application. The AFM ap-
plications have the possibility to detect the early subtle
changes before significant pathology occur and to give
the decision which time to terminate the treatment.
Thus, to a certain extent, it is interesting to employ
AFM to analysis the biological characteristics of Treg
cells after allo-HSCT to further understand the possible
mechanisms and role of Treg cells in the treatment and
development of GVHD.
In this study, we demonstrated that AFM could be
used to simultaneously observe the single membrane
proteins and find the details of their surface structures.
A common approach to the identification and isolation
of Treg cells is the use of CD4+ and CD25+. The Treg
cells population represents 2 ~ 10% of all CD4+ cells.
Only a subset of CD25+ (the alpha chain of the IL-2
receptor), mostly cells with the highest levels of expres-
sion, is considered to be Treg cells [20]. Although the
transcription factor forkhead box P3 (FoxP3) is a very
specific marker of regulatory T cells [21], it is an intra-
cellular protein, and the detection of FoxP3 requires per-
meabilizing the cell membrane. So it cannot be used for
sorting the Treg cells without the damage of cell mem-
brane. Thus, we used CD4 + CD25+ Treg cells isolation
Kit for sorting the Treg cells. The cell surface ultrastruc-
ture of CD4 + CD25+ cells at GVHD onset exhibited a
regular nanoscale network, and this heterogeneous struc-
ture represented a composite of the plasma membrane.
And we found that obvious morphological differences
occurred in Treg cells without GVHD. The alteration ofthe cell membrane structure could directly influence the
cell function. As one of the advantages of the AFM, it can
detect cell membrane proteins and study cell surface
structures [11]. By comparing the topography details of
the Treg cells surface with GVHD and without GVHD, we
found that the multiple irregular microspikes could be ob-
served on the surface of Treg cells in patients without
GVHD. The irregular microspikes or nano clusters might
be the ultrastructure membrane proteins. These results
indicated that such remarkable biological morphology
changes in the cell membrane structure of Treg cells
might be related to specific activation of Treg cells which
could inhibit the development of GVHD. The absence of
such the microspikes or nano clusters in Treg cells surface
with GVHD might be related to the functional inactiva-
tion or dysfunction of Treg cells in GVHD status, and
related to the occurrence and development of GVHD.
The mechanical stiffness of individual cells is impor-
tant in tissue homeostasis, cell growth, division and mo-
tility, and the epithelial-mesenchymal transition in the
initiation of cancer [22]. In this study, we found that the
rigidity of Treg cells from patients with GVHD were
similar to Treg cells without GVHD by the detection of
adhesion force. That means the biomechanical proper-
ties of Treg cells might not be changed significantly on
GVHD onset. Even changes in the adhesion force of
Treg cells at the beginning of the GVHD were slight, the
membrane structure of cell surface had already varied
widely, and moreover, the biological morphology changes
in the cell membrane structure of Treg cells would
certainly cause the physical-mechanical properties changes
subsequently with the progress of GVHD. However, further
investigation is needed to confirm the physical-mechanical
properties changes in Treg cells with GVHD.
Conclusions
In summary, we compared the morphological feature of
Treg cells between patients with GVHD onset and with-
out GVHD by using high resolution AFM imaging
mode. The imaging mode allowed us to visualize cell
surface properties at nanometer scale as a potential clin-
ical tool for early stage of the GVHD. The research on
the changes in cell ultrastructure could help us better
understand the structure-function relationships. The
study implied the possibility of AFM applications to de-
tect the early subtle changes before significant pathology
occur and to give the decision which time to terminate
the treatment.
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